Dendritic cells: therapy and imaging

Pham, Wellington; Kobukai, Saho; Hotta, Chie; Gore, John C.

doi:10.1517/14712590902867739

Cited by 20 publications

(6 citation statements)

References 211 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…and i.n. injections were comparable and that even less than 5.10 5 DC was enough to induce an immune response [136,137]. So in our opinion, it is more attractive to perform i.d.…”

Section: Strategies Currently In Clinical Trialsmentioning

confidence: 61%

Role of Dendritic Cells in HIV-Immunotherapy

Gulck¹,

Tendeloo²,

Berneman³

et al. 2010

CHR

View full text Add to dashboard Cite

HIV remains one of the most important deadly infections today, due to the lack of a preventive vaccine and limited access to medical care in developing countries. In developed countries, antiretroviral therapy is available, but it can not eliminate the virus, implying that life-long therapy is necessary. Therefore, it is important that other strategies such as therapeutic vaccination will be developed to control virus replication or even eliminate the virus. The major obstacles towards such a strategy are the huge variability of the virus and the profound HIV-induced immune dysfunction. In this review we focus on dendritic cell based immunotherapies against HIV. To develop an efficient immunotherapy, several elements should be taken into account such as which antigen and loading strategy to use, how to deliver the immunogen, how to optimize the interaction between antigenic peptide and T cells and avoid tolerance. Clearly, to develop an immunotherapy to complement the effect of HAART, it is not sufficient to enhance T cell responses against a consensus sequence or against the prevailing plasma virus. Broad and potent immune response are needed to suppress the entire quasispecies, including the latent reservoir, and to prevent any escape.

show abstract

“…and i.n. injections were comparable and that even less than 5.10 5 DC was enough to induce an immune response [136,137]. So in our opinion, it is more attractive to perform i.d.…”

Section: Strategies Currently In Clinical Trialsmentioning

confidence: 61%

Role of Dendritic Cells in HIV-Immunotherapy

Gulck¹,

Tendeloo²,

Berneman³

et al. 2010

CHR

View full text Add to dashboard Cite

show abstract

“…To accomplish their biological functions, the DCs undergo a complex pattern of migration which includes their localization to both peripheral non-lymphoid tissues and secondary lymphoid organs. In the absence of correct tissue localization, the DCs fail to promote proper immune responses [34-37]. Thus, we studied the trafficking and homing pattern of primary DC-vaccine in BALB/c mouse strain.…”

Section: Discussionmentioning

confidence: 99%

In vivo trafficking and immunostimulatory potential of an intranasally-administered primary dendritic cell-based vaccine

et al. 2010

View full text Add to dashboard Cite

BackgroundCoccidioidomycosis or Valley fever is caused by a highly virulent fungal pathogen: Coccidioides posadasii or immitis. Vaccine development against Coccidioides is of contemporary interest because a large number of relapses and clinical failures are reported with antifungal agents. An efficient Th1 response engenders protection. Thus, we have focused on developing a dendritic cell (DC)-based vaccine for coccidioidomycosis. In this study, we investigated the immunostimulatory characteristics of an intranasal primary DC-vaccine in BALB/c mouse strain that is most susceptible to coccidioidomycosis. The DCs were transfected nonvirally with Coccidioides-Ag2/PRA-cDNA. Expression of DC-markers, Ag2/PRA and cytokines were studied by flow cytometry, dot-immunoblotting and cytometric bead array methods, respectively. The T cell activation was studied by assessing the upregulation of activation markers in a DC-T cell co-culture assay. For trafficking, the DCs were co-transfected with a plasmid DNA encoding HSV1 thymidine kinase (TK) and administered intranasally into syngeneic mice. The trafficking and homing of TK-expressing DCs were monitored with positron emission tomography (PET) using 18F-FIAU probe. Based on the PET-probe accumulation in vaccinated mice, selected tissues were studied for antigen-specific response and T cell phenotypes using ELISPOT and flow cytometry, respectively.ResultsWe found that the primary DCs transfected with Coccidioides-Ag2/PRA-cDNA were of immature immunophenotype, expressed Ag2/PRA and activated naïve T cells. In PET images and subsequent biodistribution, intranasally-administered DCs were found to migrate in blood, lung and thymus; lymphocytes showed generation of T effector memory cell population (TEM) and IFN-γ release.ConclusionsIn conclusion, our results demonstrate that the intranasally-administered primary DC vaccine is capable of inducing Ag2/PRA-specific T cell response. Unique approaches utilized in our study represent an attractive and novel means of producing and evaluating an autologous DC-based vaccine.

show abstract

“…Disadvantages are the modest spatial resolution of the imaging and the fact that the technique is suitable only for animal studies. 16 Various enzymes, receptors and membrane transporters (Herpes simplex virus I, thymidine kinase, dopamine type 2 receptor, Na + /I − symporter, etc.) have been used as reporters for use in nuclear-based imaging techniques.…”

Section: Cell-labeling Probesmentioning

confidence: 99%